PharmaEssentia
Market Cap
NT$24.0b
Last Updated
2021/01/26 17:20 UTC
Data Sources
Company Financials +
Executive Summary
PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Share Price & News
How has PharmaEssentia's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6446 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 6446's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
-0.9%
6446
-0.3%
TW Biotechs
2.0%
TW Market
1 Year Return
-20.3%
6446
22.9%
TW Biotechs
31.2%
TW Market
Return vs Industry: 6446 underperformed the TW Biotechs industry which returned 22.9% over the past year.
Return vs Market: 6446 underperformed the TW Market which returned 31.2% over the past year.
Shareholder returns
| 6446 | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.9% | -0.3% | 2.0% |
| 30 Day | -4.0% | -6.1% | 10.6% |
| 90 Day | 13.6% | -0.3% | 22.8% |
| 1 Year | -20.3%-20.3% | 23.3%22.9% | 35.8%31.2% |
| 3 Year | -40.0%-40.0% | -18.1%-19.5% | 58.3%40.5% |
| 5 Year | -47.7%-47.7% | -51.3%-51.7% | 133.0%92.1% |
Long-Term Price Volatility Vs. Market
How volatile is PharmaEssentia's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?1 month ago | Simply Wall St
PharmaEssentia Corporation's (GTSM:6446) Profit Outlook3 months ago | Simply Wall St
Despite Lacking Profits PharmaEssentia (GTSM:6446) Seems To Be On Top Of Its DebtValuation
Is PharmaEssentia undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 6446 (NT$90.8) is trading below our estimate of fair value (NT$417.47)
Significantly Below Fair Value: 6446 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 6446 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 6446 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6446's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6446 is good value based on its PB Ratio (4x) compared to the TW Biotechs industry average (4.8x).
Next Steps
Future Growth
How is PharmaEssentia forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
90.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6446 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Earnings vs Market: 6446 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6446's is expected to become profitable in the next 3 years.
Revenue vs Market: 6446's revenue (95.9% per year) is forecast to grow faster than the TW market (11.2% per year).
High Growth Revenue: 6446's revenue (95.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6446's Return on Equity is forecast to be low in 3 years time (17.8%).
Next Steps
Past Performance
How has PharmaEssentia performed over the past 5 years?
-4.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6446 is currently unprofitable.
Growing Profit Margin: 6446 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6446 is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare 6446's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6446 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 6446 has a negative Return on Equity (-24.09%), as it is currently unprofitable.
Next Steps
Financial Health
How is PharmaEssentia's financial position?
Financial Position Analysis
Short Term Liabilities: 6446's short term assets (NT$5.1B) exceed its short term liabilities (NT$897.8M).
Long Term Liabilities: 6446's short term assets (NT$5.1B) exceed its long term liabilities (NT$496.5M).
Debt to Equity History and Analysis
Debt Level: 6446's debt to equity ratio (1.6%) is considered satisfactory.
Reducing Debt: 6446's debt to equity ratio has reduced from 12.4% to 1.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6446 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 6446 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is PharmaEssentia current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6446's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6446's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6446's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6446's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6446's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.0yrs
Average management tenure
CEO
Ko-Chung Lin
4yrs
Tenure
Mr. Ko-Chung Lin, Ph.D., is the Founder & Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. Mr. Lin served as Managing Director of Global...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Pharmaceutical Officer | no data | no data | no data | |
| Founder | 4yrs | no data | no data | |
| President | 5.67yrs | no data | no data | |
| Accounting Manager & Senior Manager of Finance | 5.25yrs | no data | no data | |
| Chief Medical Officer | 4yrs | no data | no data | |
| Head of Japan Medical Affairs | 2.5yrs | no data | no data | |
| Chief Operating Officer of Taichung Plant | 2.5yrs | no data | no data | |
| Head of Clinical Development & Medical Affairs for U.S. Subsidiary | 0.25yr | no data | no data |
4.0yrs
Average Tenure
Experienced Management: 6446's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Pharmaceutical Officer | no data | no data | no data | |
| President | 5.67yrs | no data | no data | |
| Independent Director | 6.83yrs | no data | no data | |
| Director | 11.58yrs | no data | no data | |
| Director | 14.58yrs | no data | no data | |
| Independent Director | 6.83yrs | no data | no data | |
| Director | 14.58yrs | no data | no data | |
| Director | 8.33yrs | no data | no data | |
| Director | 14.58yrs | no data | no data | |
| Independent Director | 2.58yrs | no data | no data | |
| Director | 1yr | no data | no data |
7.6yrs
Average Tenure
Experienced Board: 6446's board of directors are considered experienced (7.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.1%.
Top Shareholders
Company Information
PharmaEssentia Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: PharmaEssentia Corporation
- Ticker: 6446
- Exchange: GTSM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$24.024b
- Shares outstanding: 263.42m
- Website: https://www.pharmaessentia.com
Location
- PharmaEssentia Corporation
- No. 3, park Street
- 2nd Floor-5
- Taipei
- 115
- Taiwan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 6446 | GTSM (Taipei Exchange) | Yes | Common Shares | TW | TWD | Mar 2014 |
Biography
PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases. Its products include ropeginterferon alfa-2b that is used ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/26 17:20 |
| End of Day Share Price | 2021/01/26 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.